The PK/PD Study of SHR2285 Tablets in Healthy Subjects
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
Thrombosis is a maladaptive process of vascular occlusion and remains a primary cause of
cardiovascular morbidity and mortality, The dose-limiting issue with available anticoagulant
therapies is bleeding. The primary objective of this study is to assess the safety and
tolerability of SHR2285 tablets in healthy subjects. In addition, this study will provide
information on Pharmacokinetics and Pharmacodynamics of SHR2285 tablets in healthy subjects.